TY - JOUR
T1 - Analyzing the mechanism of Rap1 activation in platelets
T2 - Rap1 activation is related to the release reaction mediated through the collagen receptor GPVI
AU - Jung, Stephanie M.
AU - Ohnuma, Masaaki
AU - Watanabe, Naohide
AU - Sonoda, Mamiko
AU - Handa, Makoto
AU - Moroi, Masaaki
N1 - Funding Information:
This work was supported by grants-in-aid for scientific research and MEXT.HAITEKU (2004–2008) program from the Japanese Ministry of Education, Culture, Sports, Science, and Technology and by a grant from Mitsubishi Pharma Research Foundation.
PY - 2006
Y1 - 2006
N2 - The abundant Rap1 in platelets becomes activated when these cells are stimulated by various agonists, but its function has remained unknown. In view of this, we developed an assay to quantitatively measure activated Rap1 and used it to determine relationships between Rap1 activation and several platelet functions: integrin α2β1 activation, tyrosine phosphorylation, and the release reaction. We looked at how these processes are affected by the protein kinase C inhibitor BIMI, tyrosine kinase inhibitor PP2, PI 3-kinase inhibitor wortmannin, and ADP scavenger apyrase. In CRP (collagen related peptide)-activated platelets, all the inhibitors severely inhibited Rap1 activation, but had little effect on integrin α2β1 activation, indicating that the integrin activation mechanism is different from the Rap1 activation mechanism, at least in GPVI-dependent activation. With p85α-null mouse platelets, we demonstrated that Rap1 activation involves PI 3-kinase p85α-dependent tyrosine phosphorylation. All the inhibitors similarly decreased Rap1 activation and the serotonin release reaction, and the inhibition of Rap1 activation was not due to the lack of released ADP. Our results indicate that platelet Rap1 activation is closely related to the release reaction and not to integrin α2β1 activation in GPVI-mediated platelet activation.
AB - The abundant Rap1 in platelets becomes activated when these cells are stimulated by various agonists, but its function has remained unknown. In view of this, we developed an assay to quantitatively measure activated Rap1 and used it to determine relationships between Rap1 activation and several platelet functions: integrin α2β1 activation, tyrosine phosphorylation, and the release reaction. We looked at how these processes are affected by the protein kinase C inhibitor BIMI, tyrosine kinase inhibitor PP2, PI 3-kinase inhibitor wortmannin, and ADP scavenger apyrase. In CRP (collagen related peptide)-activated platelets, all the inhibitors severely inhibited Rap1 activation, but had little effect on integrin α2β1 activation, indicating that the integrin activation mechanism is different from the Rap1 activation mechanism, at least in GPVI-dependent activation. With p85α-null mouse platelets, we demonstrated that Rap1 activation involves PI 3-kinase p85α-dependent tyrosine phosphorylation. All the inhibitors similarly decreased Rap1 activation and the serotonin release reaction, and the inhibition of Rap1 activation was not due to the lack of released ADP. Our results indicate that platelet Rap1 activation is closely related to the release reaction and not to integrin α2β1 activation in GPVI-mediated platelet activation.
KW - GPVI
KW - Integrin activation
KW - Platelets
KW - Rap1
KW - Release reaction
UR - http://www.scopus.com/inward/record.url?scp=33747872565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33747872565&partnerID=8YFLogxK
U2 - 10.1016/j.thromres.2005.11.002
DO - 10.1016/j.thromres.2005.11.002
M3 - Article
C2 - 16380154
AN - SCOPUS:33747872565
SN - 0049-3848
VL - 118
SP - 509
EP - 521
JO - Thrombosis Research
JF - Thrombosis Research
IS - 4
ER -